# Study to Evaluate the Immunogenicity of LR20062 Compared to Control When Administered Intramuscularly in Healthy Infants At 2, 4, 6 Months of Age

> **NCT06618196** · PHASE2 · NOT_YET_RECRUITING · sponsor: **LG Chem** · enrollment: 336 (estimated)

## Conditions studied

- Diphtheria
- Tetanus
- Pertussis
- Hepatitis B
- Poliomyelitis
- Haemophilus Influenzae Type B Infection

## Interventions

- **BIOLOGICAL:** LR20062
- **BIOLOGICAL:** DTaP-HepB-IPV-Hib vaccine

## Key facts

- **NCT ID:** NCT06618196
- **Lead sponsor:** LG Chem
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-10-02
- **Primary completion:** 2025-06-30
- **Final completion:** 2026-04-30
- **Target enrollment:** 336 (ESTIMATED)
- **Last updated:** 2024-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06618196

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06618196, "Study to Evaluate the Immunogenicity of LR20062 Compared to Control When Administered Intramuscularly in Healthy Infants At 2, 4, 6 Months of Age". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06618196. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*